Please assess the completion status of the following clinical trial:

Trial Title: Study of Rifaximin in Minimal Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years~* cirrhosis diagnosed by clinical or biopsy grounds~* Minimal hepatic encephalopathy defined by impaired performance on at least 2 of the following: number connection tests A/B, digit symbol and block design tests (NCT-A, NCT-B, DST and BDT) compared to age and education-matched controls.~* No contraindications to MRI~* TIPS (transjugular intra-hepatic porto-systemic shunt) procedure or elective surgery planned within the next 8 weeks~Exclusion Criteria:~* Current therapy with lactulose, rifaximin or other treatment for hepatic encephalopathy.~* Prior episodes of overt HE~* MMSE \<25~* TIPS placement~* Unable to give informed consent.~* Contra-indications to MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).